Martin Shkreli won't cut individual Daraprim price after all

Before you go, we thought you'd like these...
Before you go close icon
Martin Shkreli Won't Cut Individual Daraprim Price After All



Remember Martin Shkreli, arguably the most hated man in pharmaceuticals for raising the cost of a drug HIV patients regularly take by 5,000 percent? Well, he's getting some very unwanted attention again.

Shkreli is the Turing Pharmaceuticals CEO who inflated the cost of the parasite-fighting and lifesaving drug Daraprim from $13.50 to $750.

For more on Martin Shkreli​ scroll through the gallery below:
6 PHOTOS
Pharma CEO Martin Shkreli
See Gallery
Martin Shkreli won't cut individual Daraprim price after all
Martin Shkreli, chief investment officer of MSMB Capital Management, sits for a photograph in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli, chief investment officer of MSMB Capital Management, sits behind a chess board in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
Martin Shkreli, chief investment officer of MSMB Capital Management, works on a computer in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker's top management if successful. Photographer: Paul Taggart/Bloomberg via Getty Images ***Local Caption ** Martin Shkreli
"THEY SEE ME ROLLING..." http://t.co/D1mDBEeZMq
Turing Pharma Puppy Party 2015 http://t.co/0xf1zKUYXy
HIDE CAPTION
SHOW CAPTION
of
SEE ALL
BACK TO SLIDE


Patients, the medical community and the media blasted Shkreli for the move, and eventually he did say he'd reverse the price increase.

But on Wednesday his company said in a press release that it would drop prices by 50 percent for hospitals, create smaller bottles with 30 pills and provide free starter packs in 2016. The company also said, "We pledge that no patient needing Daraprim will ever be denied access."

Sounds nice, right? Well, these changes might only affect bulk buys, since it seems as if the $750 price per pill is unchanged.

Shkreli previously said the company needed to increase the pill's price so it could do studies to improve the drug. But critics have questioned his company's ability to do sound scientific research.

Some presidential hopefuls have even used Shkreli and Turing as a part of their platforms for health care or a conversation about how they could regulate the pharmaceutical industry to avoid price hikes like these in the future.

This video includes an image from the U.S. National Library of Medicine.

More from AOL.com:
AP FACT CHECK: On climate science, most GOP candidates fail
Balloons, floats as NYC Thanksgiving parade gets underway
hris Hemsworth paid off his parents' debts

Read Full Story

Sign up for Breaking News by AOL to get the latest breaking news alerts and updates delivered straight to your inbox.

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners

Man's Wife Leaves Him And Their Kids After A Fight - Two Days Later He Posts This Man's Wife Leaves Him And Their Kids After A Fight - Two Days Later He Posts This
15 Recall the Kindest Thing a Stranger Ever Did for Them 15 Recall the Kindest Thing a Stranger Ever Did for Them
Man Finds 5 Abandoned 'Puppies' In His Garden - Then Quickly Realizes He Made A Big Man Finds 5 Abandoned 'Puppies' In His Garden - Then Quickly Realizes He Made A Big